Neurotech International (ASX:NTI) has announced positive results from its recently completed 28-day Good Laboratory Practice oral toxicology studies evaluating its lead drug candidate NTI164.
Neurotech says NTI164 shows positive tolerability in key preclinical toxicology studies
May 5, 2025 Australian Biotech
Latest Video
New Stories
-
Merck joins with Omico to improve access to cancer trials in Australia
May 22, 2025 - - Latest News -
New Zealand announces 12-month prescriptions in 2025 Budget
May 22, 2025 - - Latest News -
'I think we have to step up and help him to understand that he's got to deliver on it'
May 22, 2025 - - Latest News -
TGA approves first-of-a-kind medicine for early symptomatic Alzheimer’s disease
May 21, 2025 - - Latest News -
Examples are important as evidence of the problem, but be prepared to defend them
May 21, 2025 - - Latest News -
Trump administration invites companies to 'align' US pricing under MFN plan
May 21, 2025 - - Latest News -
NDIS minister restates the importance of 'nothing about us, without us!'
May 20, 2025 - - Latest News